Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Atezolizumab + Bevacizumab for Recurrent Liver Cancer Post-Transplant
NCT05833126Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC). Primary endpoints: Acute graft rejection rate at 3 months and Objective Response Rate at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05833126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833126.